Search Results

Showing results 161 - 170 for 1029

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. | Pathology & Laboratory Medicine

...Horwitz S Journal Leuk Lymphoma Volume 60 Issue 7 Pagination 1626-1631 Date Published 2019 07 ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/combined-use-tofacitinib-pan-jak-inhibitor-and-ruxolitinib-jak12-inhibitor

The application of precision medicine in diagnosing familial Mediterranean fever. | Pathology & Laboratory Medicine

...Beltran H Journal Leuk Lymphoma Volume 60 Issue 8 Pagination 2091-2093 Date Published 2019 08 ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/application-precision-medicine-diagnosing-familial-mediterranean-fever

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. | Pathology & Laboratory Medicine

...Cerchietti L Journal Leuk Lymphoma Volume 59 Issue 1 Pagination 256-258 Date Published 2018 01 ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/eif4e-inhibitor-ribavirin-potential-antilymphoma-therapeutic-early-clinical

Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of mutation and genetic complexity. | Pathology & Laboratory Medicine

..., Aqil B, Chen Q, Chen Y-H Journal Leuk Lymphoma Pagination 1-4 Date Published 2021 Jul 14 ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/mast-cell-sarcoma-transdifferentiated-clonally-related-t-lymphoblastic

Smith, Craig R

...Journal of the American College of Cardiology. 2012 Review GET IT Times cited: 1029 2012 ACCF/AHA/ACP...

http://vivo.med.cornell.edu/display/cwid-smithcr

Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant. | Pathology & Laboratory Medicine

...Gergis U Journal Leuk Lymphoma Volume 61 Issue 12 Pagination 2894-2899 Date Published 2020 12 ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/poor-graft-function-after-t-cell-depleted-allogeneic-hematopoietic-stem-cell

Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. | Pathology & Laboratory Medicine

...Besien K Journal Leuk Lymphoma Volume 59 Issue 12 Pagination 2829-2835 Date Published 2018 12 ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/comparison-time-engraftment-between-autologous-patients-receiving-washed

PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. | Pathology & Laboratory Medicine

...Bertoni F Journal Leuk Lymphoma Volume 56 Issue 5 Pagination 1223-8 Date Published 2015 May ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/prdm1blimp1-tumor-suppressor-gene-b-and-t-cell-lymphomas

Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. | Pathology & Laboratory Medicine

...Chadburn A Journal Leuk Lymphoma Volume 57 Issue 7 Pagination 1731-4 Date Published 2016 07 ISSN 1029...

https://pathology.weill.cornell.edu/research/publications/plasmablastic-lymphoma-treatable-haart-era-10-year-retrospective-aids

A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. | Population Health Sciences

..., Chen-Kiang S, Leonard JP Journal Leuk Lymphoma Pagination 1-5 Date Published 2019 May 23 ISSN 1029...

https://phs.weill.cornell.edu/research-collaboration/publications/phase-i-trial-palbociclib-plus-bortezomib-previously-treated

Showing results 161 - 170 for 1029